
Bloomlife
Women's health company combining clinically validated wearables with data analytics to improve birth outcomes.
- B2C
- manufacturing
- commission
- health
- education
- medical devices
- hardware
- deep tech
- computer vision
- connected device
- iot internetofthings
- artificial intelligence
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor investor investor investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | $12.2m | Series A | |
Total Funding | 000k |
Related Content
Bloomlife is a maternal health technology company that provides a remote prenatal care platform for healthcare providers. It was co-founded in 2014 by CEO Eric Dy, PhD, and COO Julien Penders, MSc. Dy, a biomedical engineer, was personally motivated by his wife's high-risk pregnancy, which involved several complications and their son's subsequent stay in the NICU. This experience highlighted the fragmented nature of maternal care and inspired him to partner with Penders, a colleague from the European R&D institute imec, where they both had experience developing advanced wearable sensors and mobile health technology.
The company initially launched a direct-to-consumer wearable that allowed expectant mothers to track contractions from home. This first product was designed to automatically time, count, and measure contractions, sending the data to a smartphone app to help women understand their body's preparation for labor. After recognizing that healthcare providers were more focused on managing high-risk pregnancies, Bloomlife pivoted its strategy from a B2C to a B2B2C model in 2020. This involved shifting from a consumer wellness device to a clinical, prescription-based platform.
The core of Bloomlife's current offering is the FDA-cleared MFM-Pro, a prescription wearable patch that non-invasively monitors both maternal and fetal heart rates outside of a clinical setting. The platform is designed to replace manual processes and frequent in-clinic appointments with a comprehensive remote monitoring solution. It integrates with third-party devices to manage conditions like hypertension and diabetes, and also includes screenings for maternal mental health. The business model involves contracting with healthcare providers, such as health systems and private practices, who prescribe the service to their patients. Bloomlife manages the logistics, while the clinical teams interpret the data, which is integrated into their existing electronic medical record (EMR) workflows. Revenue is generated by sharing in the reimbursement that providers receive from insurance companies for remote patient monitoring services.
Keywords: remote patient monitoring, maternal health, prenatal care, femtech, wearable sensors, fetal monitoring, high-risk pregnancy, digital health, FDA cleared, connected devices